Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.

Barbour AM, Sarov-Blat L, Cai G, Fossler MJ, Sprecher DL, Graggaber J, McGeoch AT, Maison J, Cheriyan J.

Br J Clin Pharmacol. 2013 Jul;76(1):99-106. doi: 10.1111/bcp.12063.

2.

Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.

Yang S, Lukey P, Beerahee M, Hoke F.

Clin Pharmacokinet. 2013 Mar;52(3):187-98. doi: 10.1007/s40262-012-0025-6.

PMID:
23254770
3.

Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.

Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, Cai G, de Winter RJ, Hamm CW, Heitner JF, Kim R, Lerman A, Patel MR, Tanguay JF, Lepore JJ, Al-Khalidi HR, Sprecher DL, Granger CB; SOLSTICE Investigators.

Lancet. 2014 Sep 27;384(9949):1187-95. doi: 10.1016/S0140-6736(14)60417-7. Epub 2014 Jun 12. Erratum in: Lancet. 2014 Sep 27;384(9949):1186.

PMID:
24930728
4.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of losmapimod in healthy Japanese volunteers.

Ino H, Takahashi N, Terao T, Igarashi H, Sarai N.

Clin Pharmacol Drug Dev. 2015 Jul;4(4):262-9. doi: 10.1002/cpdd.190. Epub 2015 May 7.

PMID:
27136906
5.

Losmapimod concentration-QT relationship in healthy volunteers: meta-analysis of data from six clinical trials.

Yang S, Beerahee M.

Eur J Clin Pharmacol. 2013 Jun;69(6):1261-7. doi: 10.1007/s00228-012-1469-1. Epub 2013 Jan 17.

PMID:
23325437
6.

Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.

Hoover R, Hunt T, Benedict M, Paulson SK, Lawrence L, Cammarata S, Sun E.

Clin Ther. 2016 Jan 1;38(1):53-65. doi: 10.1016/j.clinthera.2015.11.019. Epub 2015 Dec 21.

7.

Utility of concentration-effect modeling and simulation in a thorough QT study of losmapimod.

Barbour AM, Magee M, Shaddinger B, Arya N, Tombs L, Tao W, Patel BR, Fossler MJ, Glaser R.

J Clin Pharmacol. 2015 Jun;55(6):661-70. doi: 10.1002/jcph.465. Epub 2015 Feb 13.

PMID:
25612153
8.

Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.

Namour F, Vanhoutte FP, Beetens J, Blockhuys S, De Weer M, Wigerinck P.

Drugs R D. 2012 Sep 1;12(3):141-63. doi: 10.2165/11633120-000000000-00000.

9.

Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.

Retlich S, Duval V, Ring A, Staab A, Hüttner S, Jungnik A, Jaehde U, Dugi KA, Graefe-Mody U.

Clin Pharmacokinet. 2010 Dec;49(12):829-40. doi: 10.2165/11536620-000000000-00000.

PMID:
21053992
10.

The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale.

Melloni C, Sprecher DL, Sarov-Blat L, Patel MR, Heitner JF, Hamm CW, Aylward P, Tanguay JF, DeWinter RJ, Marber MS, Lerman A, Hasselblad V, Granger CB, Newby LK.

Am Heart J. 2012 Nov;164(5):646-653.e3. doi: 10.1016/j.ahj.2012.07.030. Epub 2012 Oct 16.

PMID:
23137494
11.

Absolute Bioavailability of Tasimelteon.

Torres R, Dressman MA, Kramer WG, Baroldi P.

Am J Ther. 2015 Sep-Oct;22(5):355-60. doi: 10.1097/MJT.0000000000000195.

PMID:
25658956
12.

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Stangier J, Rathgen K, Stähle H, Gansser D, Roth W.

Br J Clin Pharmacol. 2007 Sep;64(3):292-303. Epub 2007 May 15.

13.

Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.

Guo B, Wu X, Zhang Y, Shi Y, Yu J, Cao G, Zhang J.

Clin Drug Investig. 2012 Jul 1;32(7):475-86. doi: 10.2165/11632780-000000000-00000.

PMID:
22650326
14.

Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular, and Intravenous Administration of Levosulpiride After Single and Multiple Dosing in Healthy Chinese Volunteers.

Xu M, Zhou Y, Ni Y, He X, Li H, Sattar H, Chen H, Li W.

Clin Ther. 2015 Nov 1;37(11):2458-67. doi: 10.1016/j.clinthera.2015.08.024. Epub 2015 Sep 26.

PMID:
26404395
15.

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.

O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA; LATITUDE-TIMI 60 Investigators.

JAMA. 2016 Apr 19;315(15):1591-9. doi: 10.1001/jama.2016.3609.

PMID:
27043082
16.

An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.

Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, Barnacle H, Barnes NC, Tal-Singer R; Losmapimod Study Investigators.

J Clin Pharmacol. 2012 Mar;52(3):416-24. doi: 10.1177/0091270010397050. Epub 2011 Nov 16.

PMID:
22090363
17.

Comparative pharmacokinetics and bioavailability of gemifloxacin administered as an intravenous 200 mg formulation or an oral 320 mg tablet.

Kim MJ, Lim HS, Cho SH, Bae KS.

Clin Drug Investig. 2014 Mar;34(3):195-201. doi: 10.1007/s40261-013-0164-z.

PMID:
24385283
18.

Acute coronary syndromes: Promising data for losmapimod in NSTEMI.

Roberts A.

Nat Rev Cardiol. 2014 Aug;11(8):436. doi: 10.1038/nrcardio.2014.96. Epub 2014 Jul 1. No abstract available.

PMID:
24981141
20.

Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study.

Ostenfeld T, Krishen A, Lai RY, Bullman J, Baines AJ, Green J, Anand P, Kelly M.

Eur J Pain. 2013 Jul;17(6):844-57. doi: 10.1002/j.1532-2149.2012.00256.x. Epub 2012 Dec 14.

PMID:
23239139

Supplemental Content

Support Center